openPR Logo
Press release

Deadline on Sept. 14th coming up in Lawsuit for Investors in Bayer Aktiengesellschaft (OTC: BAYRY)

08-27-2020 12:00 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on September 14, 2020 in the lawsuit for certain investors in Bayer Aktiengesellschaft (OTC: BAYRY).

A Deadline is coming up on September 14, 2020 in the lawsuit for certain investors in Bayer Aktiengesellschaft (OTC: BAYRY).

A deadline is coming up on September 14, 2020 in the lawsuit filed for certain investors of Bayer Aktiengesellschaft (OTC: BAYRY) over alleged securities laws violations by Bayer Aktiengesellschaft (OTC: BAYRY).

Investors who purchased shares of Bayer Aktiengesellschaft (OTC: BAYRY) have certain options and there are strict and short deadlines running. Deadline: September 14, 2020. OTC: BAYRY stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of Bayer Aktiengesellschaft (OTC: BAYRY) common shares between May 23, 2016, and March 19, 2019, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 23, 2016, and March 19, 2019, the Defendants made false and misleading statements to investors, describing the Acquisition as "a compelling transaction for shareholders" that would create "significant value" by generating "stronger growth, better profitability, and a more resilient business profile" and "will translate into attractive financial benefits for Bayer and its shareholders."

The plaintiff alleges that the Defendants specifically downplayed the liability risks related to Monsanto's Roundup product, emphasizing that the Company conducted a "thorough analysis" during due diligence and "undertook appropriate due diligence of litigation and regulatory issues throughout the process" which led Bayer to finalize the Acquisition.

Those who purchased shares of Bayer Aktiengesellschaft (OTC: BAYRY) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on Sept. 14th coming up in Lawsuit for Investors in Bayer Aktiengesellschaft (OTC: BAYRY) here

News-ID: 2122233 • Views:

More Releases from Shareholders Foundation

ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly NASDAQ: SINA)
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made. If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: FLR) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp. (NYSE: SOC)
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp. Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Bayer

Regorafenib Market Analysis By Top Key Players - Bayer Pharmaceuticals, Beacon P …
The "Regorafenib Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023. Growing Demand and Growth Potential in the Global Regorafenib Market, 2024-2031 Verified Market Research's most recent report, "Regorafenib Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth examination of the
Radiopharmaceuticals Market 2022 Sales Revenue - Bracco Imaging, Bayer, Mallinck …
Global Radiopharmaceuticals Market from 2022 to 2028 launched by MarketsandResearch.biz comprises a comprehensive market analysis that encompasses key aspects of the industry and defines current market dynamics in detail. It assesses growth patterns, magnitudes, and specific business developments under the current market scenario. The best statistical surveying and investigation performed with the advanced tools and techniques in this report. The study report shows a balanced presentation of statistical and theoretical
Point of Care Molecular Diagnostics Market Industry Analysis with Abaxis, Inc., …
The Point of Care Molecular Diagnostics Market is set to exceed USD 2.5 billion by 2024; according to a new research study published by Global Market Insights, Inc. Increasing awareness regarding pre-disease diagnosis along with growing incidence of infectious diseases will drive point of care molecular diagnostics market growth. Growing R&D focused on reducing time required for molecular tests will further propel industry growth. However, long product development time and
Companies Profiled in Point of Care Molecular Diagnostics Market are Abaxis, Inc …
Global Point of Care (PoC) molecular diagnostics market is poised to witness robust growth over the forecast period. Increasing infectious diseases incidence coupled with growing public awareness levels pertaining to pre-disease detection to control its occurrence will drive PoC molecular diagnostics market growth. Quick and precise detection of causative agents is of utmost importance in infectious disease emergency cases as the inaccuracy in disease detection leads to incorrect treatment which
Companies Profiled in Point of Care Molecular Diagnostics Market are Abaxis, Inc …
Global Point of Care (PoC) molecular diagnostics market is poised to witness robust growth over the forecast period. Increasing infectious diseases incidence coupled with growing public awareness levels pertaining to pre-disease detection to control its occurrence will drive PoC molecular diagnostics market growth. Quick and precise detection of causative agents is of utmost importance in infectious disease emergency cases as the inaccuracy in disease detection leads to incorrect treatment which
Drug Delivery Market 2018 | Johnson, Bayer
Report Summary The Global Drug Delivery Market Size is primarily driven by the increasing demand for technological advanced products that are used for drug delivery, and increased number of chronic diseases in the increasing number of geriatric population. Drug delivery is referred as drug administration in the human body through injections or various other devices. Drug delivery devices are used to inject the therapeutic substances in the body with the help of